MedTrace Logo

Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation

NCT01726894 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-06-18

No results posted yet for this study

Summary

To determine the adverse events and genito-urinary side-effect profile of focal therapy to treat localised low to intermediate risk prostate cancer using irreversible electroporation (Nanoknife™).

Conditions

Interventions

DEVICE

Irreversible Electroporation

Sponsors & Collaborators

  • University College London Hospitals

    lead OTHER

Principal Investigators

  • Hashim U Ahmed, PhD · UCLH

  • Mark Emberton, Professor · UCLH

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726894 on ClinicalTrials.gov